Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax + BTK Inhibitor in Previously Treated CLL/SLL
NCT06104566Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Countries
- 19
01
Overview
A Phase 3 trial of lisaftoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Ascentage Pharma. Started Dec 2023; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06104566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104566.